BullFrog AI Holdings, Inc.
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
▼ -77.4% over 5Y.
This stock has less than 5 years of price history — the answer would measure a shorter period than the one asked for.
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 3 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Year-end price | $0.88 | $2.00 | $3.26 | |
| P/S | — | 95.8x | — | 393.7x |
| P/B | 5.2x | 5.2x | 3.8x | 9.9x |
| EPS | -$0.63 | -$0.85 | -$0.89 | |
| Profit margin | — | -5569.61% | — | -8239.80% |
| ROE | -206.61% |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| SINTSintx Technologies, Inc. | $1.50 | — | 2.1x | — | -255.86% | $10M |
| INABIn8bio Inc | $1.04 | — | 0.6x | — | -111.11% | $10.2M |
| AMSAmerican Shared Hospital Services | $1.47 | — | 0.4x | — | -12.06% | $9.78M |
| FBLGFibroBiologics, Inc. | $1.44 |
Bullfrog AI Holdings, Inc. operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform to analyze preclinical and clinical data for biotechnology and pharmaceutical companies, and other organizations. It also develops BF-222, a novel formulation of mebendazole , which is in the first phase for the treatment of Glioblastoma; BF-223, a novel prodrug of mebendazole, which is in the preclinical stage for the treatment of Glioblastoma; and BF-114, which is in the discovery phase, to treat obesity and chronic liver diseases. The company has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for use of a formulation of Mebendazole for the treatment of glioblastoma, and human cancer or neoplastic disease. It has a partnership with the Lieber Institute for Brain Development (LIBD) to enable the discovery and development of precision treatments for CNS disorders. The company was founded in 2017 and is headquartered in Gaithersburg, Maryland.
Company description provided by Yahoo Finance.
| -304.17% |
| -140.89% |
| -206.61% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| — |
| 1.9x |
| — |
| -660.08% |
| $9.59M |
| APUSApimeds Pharmaceuticals US, Inc. | $6.30 | — | 9.7x | — | — | $9.51M |
| APREAprea Therapeutics, Inc. | $0.84 | — | 0.3x | — | -46.15% | $10.56M |